MOUNTAIN VIEW, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported that ...

The RNS System is the first and only neuromodulation platform that delivers personalized, real-time seizure treatment and will be on display in booth #1642. NeuroPace presentations and activities ...

MOUNTAIN VIEW, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced ...

M.D., NeuroPace's Chief Medical Officer. "Our ongoing clinical programs aim to expand on the long-term clinical evidence of the safety and effectiveness of the RNS System, which is the only FDA ...

NeuroPace (NPCE) announced three-year effectiveness data from the Post-Approval Study, PAS, of the RNS System, which showed an 82% median reduction in seizures in adults treated with brain ...

i MOUNTAIN VIEW, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced ...

(MENAFN- GlobeNewsWire - Nasdaq) Three-year data from NeuroPace's Post-Approval Study of the RNS® System in drug-resistant focal epilepsy to be shared in oral presentation MOUNTAIN VIEW ...

M.D., NeuroPace's Chief Medical Officer.“Our ongoing clinical programs aim to expand on the long-term clinical evidence of the safety and effectiveness of the RNS System, which is the only FDA ...